Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: A 12-week, open-label prospective trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Hye Yoon | - |
dc.contributor.author | Lee, Byoung-Jo | - |
dc.contributor.author | Kim, Jong-Hoon | - |
dc.contributor.author | Bae, Jae-Nam | - |
dc.contributor.author | Hahm, Bong-Jin | - |
dc.date.available | 2020-02-29T06:44:10Z | - |
dc.date.created | 2020-02-05 | - |
dc.date.issued | 2012-03-30 | - |
dc.identifier.issn | 0278-5846 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/16513 | - |
dc.description.abstract | Background: Among patients with cancer, the management of depression is very important to improve quality of life as well as distress. Because the efficacy of escitalopram, a potent serotonin reuptake inhibitor, has not been well evaluated in cancer patients, we investigated its effects on depression and quality of life in outpatients with breast cancer. Methods: A 12-week, open-label, prospective study with escitalopram (5-20 mg/day) was performed in 79 breast cancer outpatients with depression. The primary outcome was measured using the Hamilton Depression Rating Scale (HAMD), which was administered at baseline, 1, 2, 4, 8, and 12 weeks after treatment. The Functional Assessment of Cancer Therapy-Breast (FACT-B), MD Anderson Symptoms Inventory (MDASI), Clinical Global Impression-Severity of Illness (CGI-S), and Distress Thermometer (DT) were also used to measure improvement in symptoms, distress, and quality of life. Results: Compared to baseline, HAMD, DT, and CGI-S scores were significantly decreased at week 1 and onwards, and FACT-B and MDSAI were improved at week 2 and onwards. At the end point (week 12), all FACT-B subscales including the physical, emotional, social/family, functional well-being, and the breast cancer subscales were improved. Improvement in distress and quality of life was associated with a reduction in depressive symptoms. Of all participants, 45.1% met the response criterion (at least a 50% decrease in HAMD total score), and 30.6% met the remission criterion (HAMD total score <= 7) at week 12. Conclusions: In the present study, escitalopram improved quality of life and reduced depression in breast cancer patients. Symptoms rapidly improved within 1 week, influencing quality of life. Escitalopram may be an effective treatment of depressive symptoms in breast cancer patients. (C) 2011 Elsevier Inc. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.relation.isPartOf | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | - |
dc.subject | PRIMARY-CARE PATIENTS | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | MAJOR DEPRESSION | - |
dc.subject | ONCOLOGY-GROUP | - |
dc.subject | 10 MG/DAY | - |
dc.subject | DISORDER | - |
dc.subject | PLACEBO | - |
dc.subject | PAROXETINE | - |
dc.subject | FATIGUE | - |
dc.subject | VENLAFAXINE | - |
dc.title | Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: A 12-week, open-label prospective trial | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000300135600017 | - |
dc.identifier.doi | 10.1016/j.pnpbp.2011.11.010 | - |
dc.identifier.bibliographicCitation | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, v.36, no.2, pp.318 - 323 | - |
dc.identifier.scopusid | 2-s2.0-84855358403 | - |
dc.citation.endPage | 323 | - |
dc.citation.startPage | 318 | - |
dc.citation.title | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | - |
dc.citation.volume | 36 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Kim, Jong-Hoon | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | Escitalopram | - |
dc.subject.keywordAuthor | Antidepressant | - |
dc.subject.keywordAuthor | Depression | - |
dc.subject.keywordAuthor | Quality of life | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordPlus | PRIMARY-CARE PATIENTS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | MAJOR DEPRESSION | - |
dc.subject.keywordPlus | ONCOLOGY-GROUP | - |
dc.subject.keywordPlus | 10 MG/DAY | - |
dc.subject.keywordPlus | DISORDER | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordPlus | PAROXETINE | - |
dc.subject.keywordPlus | FATIGUE | - |
dc.subject.keywordPlus | VENLAFAXINE | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.